Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

R. J. Stevens · R. Ali · C. R. Bankhead · M. A. Bethel · B. J. Cairns · R. P. Camisasca ·
F. L. Crowe · A. J. Farmer · S. Harrison · J. A. Hirst · P. Home · S. E. Kahn ·
J. H. McLellan · R. Perera · A. Plüddemann · A. Ramachandran · N. W. Roberts ·
P. W. Rose · A. Schweizer · G. Viberti · R. R. Holman

Published online: 18 October 2012
© Springer-Verlag Berlin Heidelberg 2012

Erratum to: Diabetologia DOI 10.1007/s00125-012-2653-7

The authors regret a single data transcription error at the co-ordinating centre that resulted in numerical errors in several of the reported hazard ratios for all-cause mortality. The correct values (shown in red font) in the text should have been:

Abstract: The summary RR for all-cause mortality was 0.99 (95% CI 0.83, 1.17) across all trials.

Results, All-cause mortality: RRs for all-cause mortality could be obtained for 13 trials, representing 66,447

person-years of follow-up during which 566 deaths were recorded. ... The summary RR for all-cause mortality in people randomised to metformin compared with all comparators was 0.99 (95% CI 0.83, 1.17). The summary RR for all-cause mortality was 0.91 (95% CI 0.70, 1.18) in trials comparing metformin to placebo/usual care and 1.05 (95% CI 0.84, 1.33) in trials comparing metformin to active comparators (Fig. 3). The summary RR from 1-year trials was 0.84 (95% CI 0.52, 1.38) and the summary RR from trials longer than 1 year was 1.01 (95% CI 0.84, 1.22). In a post hoc sensitivity analysis, excluding the UKPDS

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-012-2653-7>.

R. J. Stevens (✉) · C. R. Bankhead · A. J. Farmer · S. Harrison ·
J. A. Hirst · J. H. McLellan · R. Perera · A. Plüddemann ·
N. W. Roberts · P. W. Rose
Department of Primary Care Health Sciences,
University of Oxford,
Woodstock Road,
Oxford OX2 6GG, UK
e-mail: richard.stevens@phc.ox.ac.uk

R. Ali · B. J. Cairns · F. L. Crowe
Cancer Epidemiology Unit, University of Oxford,
Oxford, UK

M. A. Bethel · R. R. Holman
Diabetes Trials Unit, Oxford Centre for Diabetes Endocrinology
and Metabolism, University of Oxford,
Oxford, UK

R. P. Camisasca
TGRD Europe, Takeda Pharmaceutical Company,
London, UK

P. Home
ICM–Diabetes, The Medical School, Newcastle University,
Newcastle upon Tyne, UK

S. E. Kahn
Division of Metabolism, Endocrinology and Nutrition,
Department of Medicine, Veterans Affairs Puget Sound Health
Care System and University of Washington,
Seattle, WA, USA

A. Ramachandran
India Diabetes Research Foundation,
Dr A. Ramachandran's Diabetes Hospitals,
Egmore,
Chennai, India

A. Schweizer
Novartis Pharma,
Basel, Switzerland

G. Viberti
Unit for Metabolic Medicine, School of Medicine,
King's College London,
London, UK

Fig. 3 RRs (squares) and 95% CIs (horizontal bars) for all-cause mortality in participants in RCTs randomised to metformin compared with comparators, stratified by comparator type, with summary estimates and 95% CIs (diamonds). ^aNote that the ADOPT-G and ADOPT-R

lines represent multiple comparisons from a single trial, and the analysis takes account of correlation between these comparisons: see original text for details

sulfonylurea trial had the effect of reducing the RR for all-cause mortality in metformin compared with placebo/usual care to 0.67 (95% CI 0.49, 0.93; I^2 0.0%), and in metformin compared with any comparator to **0.91** (95% CI **0.75, 1.10**; I^2 0.0%).

A corrected version of Fig. 3 is shown above.

In addition, a typographical error appeared in Fig. 2. In the 'Study' column 'EDIT-A [43]' should have read 'EDIT [43]'.